Akums Gets CDSCO Panel Nod to Study Cilnidipine, Telmisartan FDC film-coated tablet
New Delhi: The drug major Akum Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase IV clinical trial of the fixed-dose combination (FDC) of the cardiovascular drug Cilnidipine 20mg plus Telmisartan IP 40mg film-coated tablet.
This came after the drug major Akum Pharmaceutical presented the Phase IV clinical trial protocol of cardiovascular FDC drug Cilnidipine plus Telmisartan film-coated tablet in accordance with the condition mentioned in permission in Form CT-23 dated 06.01.2023.
Cilnidipine belongs to a class of medicines called calcium channel blockers which are primarily taken for the treatment of hypertension (high blood pressure) and angina (chest pain).
Cilnidipine is a recently developed CCB and possesses both L- and N-type calcium channel-blocking activity. Since N-type calcium is distributed along the nerve and in the brain, cilnidipine is anticipated to exert specific action on nerve activity, such as inhibition of the sympathetic nervous system.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.